Transient anti-interferon autoantibodies in the airways are associated with recovery from COVID-19
Authors:
- Benjamin R. BabcockBBBenjamin R. Babcock
- Devon J. EddinsDEDevon J. Eddins
- Maria Sophia Baluyot DonaireMDMaria Sophia Baluyot Donaire
- Sannidhi SarvadhavabhatlaSSSannidhi Sarvadhavabhatla
- Vivian PaeVPVivian Pae
- Victoria W. MurrayVMVictoria W. Murray
- Gurjot GillGGGurjot Gill
- Guorui XieGXGuorui Xie
- Brian S. DoboshBDBrian S. Dobosh
- Vincent D. GiacaloneVGVincent D. Giacalone
- 6 November 2024
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (772) , eadq1789
Abstract
Preexisting anti–interferon-α (anti–IFN-α) autoantibodies in blood are associated with susceptibility to life-threatening COVID-19. However, it is unclear whether anti–IFN-α autoantibodies in the airways, the initial site of infection, can also determine disease outcomes. In this study, we developed a multiparameter technology, FlowBEAT, to quantify and profile the isotypes of anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and anti–IFN-α antibodies in longitudinal samples collected over 20 months from the airways and blood of 129 donors spanning mild to severe COVID-19. We found that nasal IgA1 anti–IFN-α autoantibodies were induced after infection onset in more than 70% of mild and moderate COVID-19 cases and were associated with robust anti–SARS-CoV-2 immunity, fewer symptoms, and efficient recovery. Nasal anti–IFN-α autoantibodies followed the peak of host IFN-α production and waned with disease recovery, revealing a regulated balance between IFN-α and anti–IFN-α response. In contrast, systemic IgG1 anti–IFN-α autoantibodies appeared later and were detected only in a subset of patients with elevated systemic inflammation and worsening symptoms. These data reveal a protective role for nasal anti–IFN-α in the immunopathology of COVID-19 and suggest that anti–IFN-α autoantibodies may serve a homeostatic function to regulate host IFN-α after viral infection in the respiratory mucosa.Keywords
All Related Versions
This publication has 52 references indexed in Scilit:
- Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytesCell Reports, 2022
- The interferon landscape along the respiratory tract impacts the severity of COVID-19Cell, 2021
- Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild diseaseImmunity, 2021
- Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor PlasmaJournal of Clinical Immunology, 2021
- Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19Cell Host & Microbe, 2020
- IgA subclasses have different effector functions associated with distinct glycosylation profilesNature Communications, 2020
- Role of IgG3 in Infectious DiseasesTrends in Immunology, 2019
- Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected MiceCell Host & Microbe, 2016
- An anti-IL-2 antibody increases serum halflife and improves anti-tumor efficacy of human recombinant interleukin-2Immunopharmacology, 1994
- Enhancement of anti-tumor activity of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2Biotherapy, 1993